We report the results of the first, to our knowledge, human clinical study that evaluated gene therapy for type 2 achromatopsia, an inherited retinal disorder caused by variants in CNGA3 and leading to cone photoreceptor dysfunction. The gene discussed is CNGA3; the disease is achromatopsia 2.